Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Conditions
Metastatic Oral Cavity Carcinoma · Recurrent Oral Cavity Carcinoma · Stage IVC Lip and Oral Cavity Cancer AJCC v8 · Head and Neck Cancer · Hypopharynx Cancer · Oropharynx Cancer · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Metastatic Hypopharyngeal Carcinoma · Metastatic Laryngeal Carcinoma · Metastatic Malignant Head and Neck Neoplasm · Metastatic Oropharyngeal Carcinoma · Recurrent Hypopharyngeal Carcinoma · Recurrent Laryngeal Carcinoma · Recurrent Malignant Head and Neck Neoplasm · Recurrent Oropharyngeal Carcinoma · Stage IVC Hypopharyngeal Carcinoma AJCC v8 · Stage IVC Laryngeal Cancer AJCC v8 · Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Katharine A. Price, MD)
Study leads
Katharine A. Price, MD
Principal Investigator
Mayo Clinic in Rochester